Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12

Eitemau Tebyg

• Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
  gan: Morales-Kastresana, Aizea, et al.
  Cyhoeddwyd: (2013)
• Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
  gan: Bolaños-Mateo, Elixabet, et al.
  Cyhoeddwyd: (2014)
• Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
  gan: Weigelin, Bettina, et al.
  Cyhoeddwyd: (2015)
• Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts
  gan: Abuqayyas, Lubna, et al.
  Cyhoeddwyd: (2012)
• Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
  gan: Stagg, John, et al.
  Cyhoeddwyd: (2011)